Skip to main content
Article thumbnail
Location of Repository

Preparation and In Vitro/In Vivo Evaluation of Vinpocetine Elementary Osmotic Pump System

By Meiying Ning, Yue Zhou, Guojun Chen and Xingguo Mei


Preparation and in vitro and in vivo evaluation of vinpocetine (VIN) elementary osmotic pump (EOP) formulations were investigated. A method for the preparation of VIN elementary osmotic pump tablet was obtained by adding organic acid additives to increase VIN solubility. VIN was used as the active pharmaceutical ingredient, lactose and mannitol as osmotic agent. Citric acid was used as increasing API solubility and without resulting in the API degradation. It is found that the VIN release rate was increasing with the citric acid amount at a constant range. Cellulose acetate 398-3 was employed as semipermeable membrane containing polyethylene glycol 6000 and diethyl-o-phthalate as pore-forming agent and plasticizer for controlling membrane permeability. In addition, a clear difference between the pharmacokinetic patterns of VIN immediate release and VIN elementary osmotic pump formulations was revealed. The area under the plasma concentration-time curve after oral administration of elementary osmotic pump formulations was equivalent to VIN immediate release formulation. Furthermore, significant differences found for mean residence time, elimination half-life, and elimination rate constant values corroborated prolonged release of VIN from elementary osmotic pump formulations. These results suggest that the VIN osmotic pump controlled release tablets have marked controlled release characters and the VIN osmotic pump controlled release tablets and the normal tablets were bioequivalent

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1955). A continuous long-term injector,”
    2. (2002). Complexation of vinpocetine with cyclodextrins in the presence or absence of polymers. Binary and ternary complexes preparation and characterization,”
    3. (1998). Drug delivery and targeting,”
    4. (1975). Elementary osmotic pump,”
    5. i b e i r o ,D .C .F e r r e i r a ,a n dF .J .B .V e i g a ,“ I nv i t r o controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets,” JournalofControlledRelease,vol.103,no.2,pp.325–339,2005.
    6. (2008). In vivo and in vitro evaluation of push-pull osmotic pump-controlled release tablet of vinpocetine using numerical deconvolution technique,”
    7. (1986). Process for increasing solubility of drug,” US patent: 4732915,
    8. (1985). Psychopharmacological effects of vinpocetine in normal healthy volunteers,”
    9. (2002). S´ ov´ ag´ o et al., “Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine,”
    10. (2003). S.Z.SzatmariandP.J.Whitehouse,“Vinpocetineforcognitive impairment and dementia,” Cochrane Database of Systematic Reviews,
    11. (2008). Solubility-modulated monolithic osmotic pump tablet for atenolol delivery,”
    12. (2004). The effect of citric acid added to hydroxypropyl methylcellulose (HPMC) matrix tablets on the release profile of vinpocetine,”
    13. (2002). Vinpocetine increases cerebral blood flow and oxygenation in stroke patients: a near infrared spectroscopy and transcranial Doppler study,”
    14. (2001). Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.